Sermorelin 10MG

Sermorelin is the acetate salt of GRF(1-29) — the 29-amino-acid active fragment of human growth hormone–releasing hormone — and it holds a distinctive place in endocrine research history as the first GHRH analog to reach formal clinical investigation. In the laboratory, it serves as the canonical reference for GHRH-receptor pharmacology: pituitary somatotroph stimulation assays, GH pulse-pattern studies, and investigations of the hypothalamic–pituitary GH axis in animal models. Compared with later analogs such as CJC-1295 (no DAC) and tesamorelin, sermorelin represents the unmodified baseline — the native-sequence fragment against which each engineering modification (DPP-IV resistance substitutions, half-life extensions) is measured. That makes it indispensable in structure-activity research on the GHRH system. Analytical characterization follows the standards for mid-length synthetic peptides: HPLC purity profiling and mass-spectrometric identity confirmation. As the historical starting point of therapeutic GHRH research, sermorelin's literature provides the baseline data that contextualizes every subsequent analog in the class. For laboratory research use only. Not for human or veterinary use.